Genetically engineered murine models - Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma

Seminars in Cancer Biology

Volumn 21, Issue 4, 2011, Pages 245-255

  Chesler, Louis ^a   Weiss, William A ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mouse models; MYCN; Neuroblastoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; BMI1 PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CLUSTERIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DICKKOPF 1 PROTEIN; DOXORUBICIN; EFLORNITHINE; ETOPOSIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; LIM KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; NORDIHYDROGUAIARETIC ACID; PLATINUM COMPLEX; PROTEIN MDM2; PROTEIN P53; REVERSAN; SELECTIN; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER GROWTH; DNA POLYMORPHISM; DRUG RESPONSE; EPIGENETICS; GENE AMPLIFICATION; GENE CONTROL; GENE DOSAGE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ENGINEERING; LOXP SITE; MICROMETASTASIS; MOLECULAR GENETICS; MYCN GENE; NEURAL CREST; NEUROBLASTOMA; NONHUMAN; ONCOGENE; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; SIGNAL TRANSDUCTION;

ANIMALS; CHILD; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; MICE; NEUROBLASTOMA; PATHOLOGY, MOLECULAR;

EID: 80655148940     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.09.011     Document Type: Review

References (157)

1. Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer 2007, 7:213-221.
2. Stratton M.R. Exploring the genomes of cancer cells: progress and promise. Science 2011, 331:1553-1558.
3. Evan G.I., Christophorou M., Lawlor E.A., Ringshausen I., Prescott J., Dansen T., et al. Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy. Cold Spring Harb Symp Quant Biol 2005, 70:263-273.
4. Grimmer M.R., Weiss W.A. Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr 2006, 18:634-638.
5. Hayward W.S., Neel B.G., Astrin S.M. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981, 290:475-480.
6. Payne G.S., Bishop J.M., Varmus H.E. Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas. Nature 1982, 295:209-214.
7. Schwab M., Alitalo K., Klempnauer K.H., Varmus H.E., Bishop J.M., Gilbert F., et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983, 305:245-248.
8. Zimmerman K.A., Yancopoulos G.D., Collum R.G., Smith R.K., Kohl N.E., Denis K.A., et al. Differential expression of myc family genes during murine development. Nature 1986, 319:780-783.
9. Sejersen T., Bjorklund H., Sumegi J., Ringertz N.R. N-myc and c-src genes are differentially regulated in PCC7 embryonal carcinoma cells undergoing neuronal differentiation. J Cell Physiol 1986, 127:274-280.
10. Ruppert C., Goldowitz D., Wille W. Proto-oncogene c-myc is expressed in cerebellar neurons at different developmental stages. EMBO J 1986, 5:1897-1901.
11. Charron J., Malynn B.A., Fisher P., Stewart V., Jeannotte L., Goff S.P., et al. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Gene Dev 1992, 6:2248-2257.
12. Moens C.B., Stanton B.R., Parada L.F., Rossant J. Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus. Development (Cambridge, England) 1993, 119:485-499.
13. Stanton B.R., Perkins A.S., Tessarollo L., Sassoon D.A., Parada L.F. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Gene Dev 1992, 6:2235-2247.
14. Knoepfler P.S., Cheng P.F., Eisenman R.N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Gene Dev 2002, 16:2699-2712.
15. Wey A., Martinez Cerdeno V., Pleasure D., Knoepfler P.S. c- and N-myc regulate neural precursor cell fate, cell cycle, and metabolism to direct cerebellar development. Cerebellum 2010, 9:537-547.
16. Malynn B.A., de Alboran I.M., O'Hagan R.C., Bronson R., Davidson L., DePinho R.A., et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Gene Dev 2000, 14:1390-1399.
17. Premsrirut P.K., Dow L.E., Kim S.Y., Camiolo M., Malone C.D., Miething C., et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 2011, 145:145-158.
18. Chayka O., Corvetta D., Dews M., Caccamo A.E., Piotrowska I., Santilli G., et al. Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst 2009, 101:663-677.
19. Schulte J.H., Horn S., Otto T., Samans B., Heukamp L.C., Eilers U.C., et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 2008, 122:699-704.
20. Dews M., Homayouni A., Yu D., Murphy D., Sevignani C., Wentzel E., et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006, 38:1060-1065.
21. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. Embo J 1997, 16:2985-2995.
22. Iwakura H., Ariyasu H., Kanamoto N., Hosoda K., Nakao K., Kangawa K., et al. Establishment of a novel neuroblastoma mouse model. Int J Oncol 2008, 33:1195-1199.
23. Hattori Y., Kanamoto N., Kawano K., Iwakura H., Sone M., Miura M., et al. Molecular characterization of tumors from a transgenic mouse adrenal tumor model: comparison with human pheochromocytoma. Int J Oncol 2010, 37:695-705.
24. Patankar S., Lazaroff M., Yoon S.O., Chikaraishi D.M. A novel basal promoter element is required for expression of the rat tyrosine hydroxylase gene. J Neurosci 1997, 17:4076-4086.
25. Alam G., Cui H., Shi H., Yang L., Ding J., Mao L., et al. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. Am J Pathol 2009, 175:856-866.
26. Teitz T., Stanke J.J., Federico S., Bradley C.L., Brennan R., Zhang J., et al. Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS ONE 2011, 6:e19133.
27. Rounbehler R.J., Li W., Hall M.A., Yang C., Fallahi M., Cleveland J.L. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 2009, 69:547-553.
28. Haraguchi S., Nakagawara A. A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse. PLoS ONE 2009, 4:e6902.
29. Chesler L., Goldenberg D.D., Collins R., Grimmer M., Kim G.E., Tihan T., et al. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 2008, 10:1268-1274.
30. Hogarty M.D., Norris M.D., Davis K., Liu X., Evageliou N.F., Hayes C.S., et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 2008, 68:9735-9745.
31. Chesler L., Goldenberg D.D., Seales I.T., Satchi-Fainaro R., Grimmer M., Collins R., et al. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 2007, 67:9435-9442.
32. Hansford L.M., Thomas W.D., Keating J.M., Burkhart C.A., Peaston A.E., Norris M.D., et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 2004, 101:12664-12669.
33. Hackett C.S., Hodgson J.G., Law M.E., Fridlyand J., Osoegawa K., de Jong P.J., et al. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 2003, 63:5266-5273.
34. Chen Z., Lin Y., Barbieri E., Burlingame S., Hicks J., Ludwig A., et al. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia 2009, 11:753-762.
35. Asano Y., Kishida S., Mu P., Sakamoto K., Murohara T., Kadomatsu K. DRR1 is expressed in the developing nervous system and downregulated during neuroblastoma carcinogenesis. Biochem Biophys Res Commun 2010, 394:829-835.
36. Balamuth N.J., Wood A., Wang Q., Jagannathan J., Mayes P., Zhang Z., et al. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Res 2010, 70:2749-2758.
37. Burkhart C.A., Watt F., Murray J., Pajic M., Prokvolit A., Xue C., et al. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res 2009, 69:6573-6580.
38. Moore H.C., Wood K.M., Jackson M.S., Lastowska M.A., Hall D., Imrie H., et al. Histological profile of tumours from MYCN transgenic mice. J Clin Pathol 2008, 61:1098-1103.
39. Cheng A.J., Cheng N.C., Ford J., Smith J., Murray J.E., Flemming C., et al. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. Eur J Cancer 2007, 43:1467-1475.
40. Lastowska M., Chung Y.J., Cheng Ching N., Haber M., Norris M.D., Kees U.R., et al. Regions syntenic to human 17q are gained in mouse and rat neuroblastoma. Gene Chromosome Cancer 2004, 40:158-163.
41. Burkhart C.A., Cheng A.J., Madafiglio J., Kavallaris M., Mili M., Marshall G.M., et al. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 2003, 95:1394-1403.
42. Dam V., Morgan B.T., Mazanek P., Hogarty M.D. Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer 2006, 6:177.
43. Morowitz M.J., Barr R., Wang Q., King R., Rhodin N., Pawel B., et al. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin Cancer Res 2005, 11:2680-2685.
44. Accorsi R., Morowitz M.J., Charron M., Maris J.M. Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma. Pediatr Radiol 2003, 33:688-692.
45. Norris M.D., Burkhart C.A., Marshall G.M., Weiss W.A., Haber M. Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol 2000, 35:585-589.
46. Weiss W.A., Godfrey T., Francisco C., Bishop J.M. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res 2000, 60:2483-2487.
47. Henderson M.J., Haber M., Porro A., Munoz M.A., Iraci N., Xue C., et al. ABCC Multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 2011, 103:1236-1251.
48. Meyer G.E., Chesler L., Liu D., Gable K., Maddux B.A., Goldenberg D.D., et al. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. J Cell Biochem 2007, 102:1529-1541.
49. Chesler L., Schlieve C., Goldenberg D.D., Kenney A., Kim G., McMillan A., et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 2006, 66:8139-8146.
50. Liu T., Tee A.E., Porro A., Smith S.A., Dwarte T., Liu P.Y., et al. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci U S A 2007, 104:18682-18687.
51. Vita M., Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006, 16:318-330.
52. Mo H., Vita M., Crespin M., Henriksson M. Myc overexpression enhances apoptosis induced by small molecules. Cell Cycle 2006, 5:2191-2194.
53. Henriksson M., Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996, 68:109-182.
54. Eilers M., Eisenman R.N. Myc's broad reach. Gene Dev 2008, 22:2755-2766.
55. Soucek L., Evan G.I. The ups and downs of Myc biology. Curr Opin Genet Dev 2010, 20:91-95.
56. Secombe J., Pierce S.B., Eisenman R.N. Myc: a weapon of mass destruction. Cell 2004, 117:153-156.
57. Gondo Y., Fukumura R., Murata T., Makino S. ENU-based gene-driven mutagenesis in the mouse: a next-generation gene-targeting system. Exp Anim 2010, 59:537-548.
58. Dupuy A.J., Akagi K., Largaespada D.A., Copeland N.G., Jenkins N.A. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 2005, 436:221-226.
59. Lawlor E.R., Soucek L., Brown-Swigart L., Shchors K., Bialucha C.U., Evan G.I. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res 2006, 66:4591-4601.
60. Boon K., Caron H.N., van Asperen R., Valentijn L., Hermus M.C., van Sluis P., et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. Embo J 2001, 20:1383-1393.
61. Mac S.M., D'Cunha C.A., Farnham P.J. Direct recruitment of N-myc to target gene promoters. Mol Carcinogen 2000, 29:76-86.
62. Grandori C., Cowley S.M., James L.P., Eisenman R.N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000, 16:653-699.
63. Murphy D.M., Buckley P.G., Bryan K., Das S., Alcock L., Foley N.H., et al. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS ONE 2009, 4:e8154.
64. Lin C.H., Jackson A.L., Guo J., Linsley P.S., Eisenman R.N. Myc-regulated microRNAs attenuate embryonic stem cell differentiation. EMBO J 2009, 28:3157-3170.
65. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
66. Bray I., Bryan K., Prenter S., Buckley P.G., Foley N.H., Murphy D.M., et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS ONE 2009, 4:e7850.
67. Shohet J.M., Ghosh R., Coarfa C., Ludwig A., Benham A.L., Chen Z., et al. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res 2011, 71:3841-3851.
68. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127:1323-1334.
69. Hemann M.T., Bric A., Teruya-Feldstein J., Herbst A., Nilsson J.A., Cordon-Cardo C., et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005, 436:807-811.
70. Jacobs J.J., Scheijen B., Voncken J.W., Kieboom K., Berns A., van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Gene Dev 1999, 13:2678-2690.
71. Cui H., Hu B., Li T., Ma J., Alam G., Gunning W.T., et al. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 2007, 170:1370-1378.
72. Giannini G., Cerignoli F., Mellone M., Massimi I., Ambrosi C., Rinaldi C., et al. High mobility group A1 is a molecular target for MYCN in human neuroblastoma. Cancer Res 2005, 65:8308-8316.
73. Eggert A., Grotzer M.A., Zuzak T.J., Wiewrodt B.R., Ikegaki N., Brodeur G.M. Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Med Pediatr Oncol 2000, 35:603-607.
74. Teitz T., Wei T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A., et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000, 6:529-535.
75. Hopkins-Donaldson S., Bodmer J.L., Bourloud K.B., Brognara C.B., Tschopp J., Gross N. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol 2000, 35:608-611.
76. Hopkins-Donaldson S., Bodmer J.L., Bourloud K.B., Brognara C.B., Tschopp J., Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000, 60:4315-4319.
77. Tanaka N., Fukuzawa M. MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells. Int J Oncol 2008, 33:815-821.
78. Vitali R., Mancini C., Cesi V., Tanno B., Mancuso M., Bossi G., et al. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models. Clin Cancer Res 2008, 14:4622-4630.
79. Airoldi I., Cocco C., Morandi F., Prigione I., Pistoia V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immunother 2008, 57:541-548.
80. Zhang L., Yeger H., Das B., Irwin M.S., Baruchel S. Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma. Neoplasia 2007, 9:36-46.
81. Leone A., Seeger R.C., Hong C.M., Hu Y.Y., Arboleda M.J., Brodeur G.M., et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 1993, 8:855-865.
82. Olive V., Bennett M.J., Walker J.C., Ma C., Jiang I., Cordon-Cardo C., et al. miR-19 is a key oncogenic component of mir-17-92. Gene Dev 2009, 23:2839-2849.
83. Tweddle D.A., Pearson A.D., Haber M., Norris M.D., Xue C., Flemming C., et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 2003, 197:93-98.
84. Carr-Wilkinson J., O'Toole K., Wood K.M., Challen C.C., Baker A.G., Board J.R., et al. High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin Cancer Res: Off J Am Assoc Cancer Res 2010, 16:1108-1118.
85. Chen L., Iraci N., Gherardi S., Gamble L.D., Wood K.M., Perini G., et al. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 2010, 70:1377-1388.
86. Keshelava N., Zuo J.J., Waidyaratne N.S., Triche T.J., Reynolds C.P. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med Pediatr Oncol 2000, 35:563-568.
87. Christophorou M.A., Martin-Zanca D., Soucek L., Lawlor E.R., Brown-Swigart L., Verschuren E.W., et al. Temporal dissection of p53 function in vitro and in vivo. Nat Genet 2005, 37:718-726.
88. Amaravadi R.K., Yu D., Lum J.J., Bui T., Christophorou M.A., Evan G.I., et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007, 117:326-336.
89. Pugh T. Exome sequencing of 81 neuroblastomas identifies a wide diversity of somatic mutation 2011, American Association for Cancer Research, Orlando, FL, USA.
90. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
91. Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
92. Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
93. George R.E., Sanda T., Hanna M., Frohling S., Luther W., Zhang J., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
94. George R.E., Attiyeh E.F., Li S., Moreau L.A., Neuberg D., Li C., et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS ONE 2007, 2:e255.
95. Mosse Y.P., Laudenslager M., Khazi D., Carlisle A.J., Winter C.L., Rappaport E., et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004, 75:727-730.
96. Bilsland J.G., Wheeldon A., Mead A., Znamenskiy P., Almond S., Waters K.A., et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol 2008, 33:685-700.
97. Pattyn A., Morin X., Cremer H., Goridis C., Brunet J.F. The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives. Nature 1999, 399:366-370.
98. Durand E., Dauger S., Pattyn A., Gaultier C., Goridis C., Gallego J. Sleep-disordered breathing in newborn mice heterozygous for the transcription factor Phox2b. Am J Resp Crit Care Med 2005, 172:238-243.
99. De Brouwer S., De Preter K., Kumps C., Zabrocki P., Porcu M., Westerhout E.M., et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res: Off J Am Assoc Cancer Res 2010, 16:4353-4362.
100. Bachetti T., Di Paolo D., Di Lascio S., Mirisola V., Brignole C., Bellotti M., et al. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma. PLoS ONE 2010, 5.
101. Stanke M., Junghans D., Geissen M., Goridis C., Ernsberger U., Rohrer H. The Phox2 homeodomain proteins are sufficient to promote the development of sympathetic neurons. Development (Cambridge, England) 1999, 126:4087-4094.
102. Raabe E.H., Laudenslager M., Winter C., Wasserman N., Cole K., LaQuaglia M., et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 2008, 27:469-476.
103. Stutterheim J., Gerritsen A., Zappeij-Kannegieter L., Kleijn I., Dee R., Hooft L., et al. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 2008, 26:5443-5449.
104. Longo L., Borghini S., Schena F., Parodi S., Albino D., Bachetti T., et al. PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma. Int J Oncol 2008, 33:985-991.
105. Beiske K., Ambros P.F., Burchill S.A., Cheung I.Y., Swerts K. Detecting minimal residual disease in neuroblastoma patients-the present state of the art. Cancer Lett 2005, 228:229-240.
106. Burchill S.A., Kinsey S.E., Picton S., Roberts P., Pinkerton C.R., Selby P., et al. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol 2001, 36:213-219.
107. Bentires-Alj M., Paez J.G., David F.S., Keilhack H., Halmos B., Naoki K., et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004, 64:8816-8820.
108. Holzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H., et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010, 142:218-229.
109. Nguyen le B., Diskin S.J., Capasso M., Wang K., Diamond M.A., Glessner J., et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet 2011, 7:e1002026.
110. Capasso M., Diskin S.J. Genetics and genomics of neuroblastoma. Cancer Treat Res 2010, 155:65-84.
111. Capasso M., Devoto M., Hou C., Asgharzadeh S., Glessner J.T., Attiyeh E.F., et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 2009, 41:718-723.
112. Maris J.M., Mosse Y.P., Bradfield J.P., Hou C., Monni S., Scott R.H., et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008, 358:2585-2593.
113. Kamp D.W., Shacter E., Weitzman S.A. Chronic inflammation and cancer: the role of the mitochondria. Oncology 2011, 25:400-410. 13.
114. Martinelli S., Carta C., Flex E., Binni F., Cordisco E.L., Moretti S., et al. Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet Cytogenet 2006, 166:124-129.
115. Wang K., Diskin S.J., Zhang H., Attiyeh E.F., Winter C., Hou C., et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 2011, 469:216-220.
116. Wu J.Y., Vlastos A.T., Pelte M.F., Caligo M.A., Bianco A., Krause K.H., et al. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. Journal international du cancer 2006, 118:1215-1226.
117. Fredlund E., Ringner M., Maris J.M., Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A 2008, 105:14094-14099.
118. Schleiermacher G., Janoueix-Lerosey I., Ribeiro A., Klijanienko J., Couturier J., Pierron G., et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol: Off J Am Soc Clin Oncol 2010, 28:3122-3130.
119. Janoueix-Lerosey I., Schleiermacher G., Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010, 29:1566-1579.
120. Schleiermacher G., Michon J., Huon I., d'Enghien C.D., Klijanienko J., Brisse H., et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer 2007, 97:238-246.
121. Liu P., Jenkins N.A., Copeland N.G. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res 2003, 13:476-484.
122. Bunting M., Bernstein K.E., Greer J.M., Capecchi M.R., Thomas K.R. Targeting genes for self-excision in the germ line. Gene Dev 1999, 13:1524-1528.
123. Brault V., Pereira P., Duchon A., Herault Y. Modeling chromosomes in mouse to explore the function of genes, genomic disorders, and chromosomal organization. PLoS Genet 2006, 2:e86.
124. Fujita T., Igarashi J., Okawa E.R., Gotoh T., Manne J., Kolla V., et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008, 100:940-949.
125. White P.S., Thompson P.M., Gotoh T., Okawa E.R., Igarashi J., Kok M., et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005, 24:2684-2694.
126. Thompson P.M., Gotoh T., Kok M., White P.S., Brodeur G.M. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003, 22:1002-1011.
127. Okawa E.R., Gotoh T., Manne J., Igarashi J., Fujita T., Silverman K.A., et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 2008, 27:803-810.
128. Liu Z., Yang X., Li Z., McMahon C., Sizer C., Barenboim-Stapleton L., et al. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Cell Death Differ 2011, 18:1174-1183.
129. Tivnan A., Tracey L., Buckley P.G., Alcock L.C., Davidoff A.M., Stallings R.L. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer 2011, 11:33.
130. Cole K.A., Attiyeh E.F., Mosse Y.P., Laquaglia M.J., Diskin S.J., Brodeur G.M., et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res: MCR 2008, 6:735-742.
131. Wei J.S., Song Y.K., Durinck S., Chen Q.R., Cheuk A.T., Tsang P., et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008, 27:5204-5213.
132. Welch C., Chen Y., Stallings R.L. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007, 26:5017-5022.
133. Stallings R.L., Foley N.H., Bryan K., Buckley P.G., Bray I. Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets 2010, 14:951-962.
134. Chen Y., Stallings R.L. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007, 67:976-983.
135. Sahin E., Depinho R.A. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010, 464:520-528.
136. Blasco M.A., Lee H.W., Rizen M., Hanahan D., DePinho R., Greider C.W. Mouse models for the study of telomerase. Ciba Found Symp 1997, 211:160-170. discussion 70-6.
137. Decock A., Ongenaert M., Vandesompele J., Speleman F. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings. Epigenetics 2011, 6.
138. Agathanggelou A., Bieche I., Ahmed-Choudhury J., Nicke B., Dammann R., Baksh S., et al. Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res 2003, 63:5344-5351.
139. Pizzo P.A., Poplack D.G. Principles and practice of pediatric oncology 2011, Wolters Kluwer/Lippincott Williams & Wilkins Health, Philadelphia. 6th ed.
140. Dyer M.A. Mouse models of childhood cancer of the nervous system. J Clin Pathol 2004, 57:561-576.
141. Jiang M., Stanke J., Lahti J.M. The connections between neural crest development and neuroblastoma. Curr Top Dev Biol 2011, 94:77-127.
142. Kawaguchi J., Nichols J., Gierl M.S., Faial T., Smith A. Isolation and propagation of enteric neural crest progenitor cells from mouse embryonic stem cells and embryos. Development (Cambridge, England) 2010, 137:693-704.
143. Lee G., Chambers S.M., Tomishima M.J., Studer L. Derivation of neural crest cells from human pluripotent stem cells. Nat Protoc 2010, 5:688-701.
144. Sauer B., Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A 1988, 85:5166-5170.
145. Tuveson D.A., Jacks T. Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 2002, 12:105-110.
146. Tuveson D.A., Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene 1999, 18:5318-5324.
147. Jacks T. Modeling cancer in the mouse. Harvey Lect 2005, 101:1-19.
148. Dymecki S.M. Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice. Proc Natl Acad Sci U S A 1996, 93:6191-6196.
149. Vooijs M., van der Valk M., te Riele H., Berns A. Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse. Oncogene 1998, 17:1-12.
150. Urlinger S., Baron U., Thellmann M., Hasan M.T., Bujard H., Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A 2000, 97:7963-7968.
151. Baron U., Bujard H. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol 2000, 327:401-421.
152. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992, 89:5547-5551.
153. Littlewood T.D., Hancock D.C., Danielian P.S., Parker M.G., Evan G.I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acid Res 1995, 23:1686-1690.
154. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830.
155. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
156. Frese K.K., Tuveson D.A. Maximizing mouse cancer models. Nat Rev Cancer 2007, 7:645-658.
157. Nishijo K., Chen Q.R., Zhang L., McCleish A.T., Rodriguez A., Cho M.J., et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 2009, 69:2902-2911.